Astellas and Pfizer’s XTANDI shows overall survival in metastatic hormone-sensitive prostate cancer
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%